Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

By G. Foster, N. Afdhal, S. Roberts, N. Bräu, E. Gane, S. Pianko, E. Lawitz, A. Thompson, M. Shiffman, C. Cooper and 25 more. New England Journal of Medicine, 2015

938 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/393d17799506afde63002a7b0481aefcb7f4d532

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

Citations in the corpus

• Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (2019, background): “Several well-designed, robust clinical trials have demonstrated the safety(147) and high curative efficacy of glecaprevir/pibrentasvir(148-158) and sofosbuvir/ velpatasvir(159-164) among treatment-naive persons without cirrhosis regardless of HCV genotype.”
• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, methodology): “treatment-experienced patients without cirrhosis and 89% (33/ 37; 4 relapses) in treatment-experienced patients with compensated cirrhosis.(128) The SVR12 rates after 12 weeks of sofosbuvir/velpatasvir were 97% (225/231) in patients without NS5A RASs at baseline vs.”
• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “m Comments: This recommendation is based on the results of the phase III ASTRAL-2 trial in patients with HCV genotype 2 infection (14% with compensated cirrhosis, 86% treatmentnaïve, 14% treatment-experienced) treated with the fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks without”